Magnesium‐Enhanced Magnetic Hyperthermia for Triggering Vaccine‐Like Antitumor Immunotherapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Zhenyuan Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, National Clinical Research Center for Oral Diseases, National Center for Stomatology, National Engineer…. Hauptthemen laut MEDLINE: Immunotherapy, Magnesium, Cancer Vaccines, Magnetite Nanoparticles. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Cancer immunotherapies, such as programmed cell death protein 1 (PD‐1) inhibitors, cancer vaccines, and chimeric antigen receptor T cells (CAR‐T cells), have become first‐line treatments for multiple tumors by eliciting antitumor immunity. However, their limited efficacy in immunosuppressive tumors, particularly Head and Neck Squamous Cell Carcinoma (HNSCC), underscores the urgent need for versatile therapeutics. Hereinto, we develop an injectable hydrogel incorporating Mg microparticles and Fe 3 O 4 magnetic nanoparticles (Mg/Fe 3 O 4 @Gel) to enhance antitumor immunotherapy, achieving potent vaccine‐like tumor suppression against both distant and newly emerging tumors. Under an alternating magnetic field, Mg/Fe 3 O 4 @Gel induces HNSCC cell death via magnetic hyperthermia, while simultaneously triggering mitochondrial dysfunction and disrupting redox homeostasis, resulting in a 72% apoptosis rate. Meanwhile, the released corrosion products effectively neutralize the intracellular acidic environment, further enhancing the efficacy of systemic immunotherapy. Mechanistic studies induce Mg/Fe 3 O 4 @Gel immunogenic cell death via Ltf regulation, facilitating effective eradication of both primary and distant lesions. Moreover, vaccination with Mg/Fe 3 O 4 @Gel‐killed tumor cells and adoptive CD3 + T cell transfer confer robust antitumor immunity, achieving 80% tumor growth suppression in immunodeficient models and surpassing typical clinical outcomes. Overall, our study highlights the potential of this metal‐based hydrogel as a universal platform to enhance antitumor efficacy through a synergistic immunotherapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, National Clinical Research Center for Oral Diseases, National Center for Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Bei…
- Department of Orthodontics, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Peking University School and Hospital of Stomatology, Beijing, China.
- School of Engineering Medicine, Beihang University, Beijing, China.
- State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing, China.
- State Key Laboratory of New Ceramics and Fine Processing, School of Materials Science and Engineering, Tsinghua University, Beijing, China.
ORCID-Profile: Zhenyuan Han, Xuelin Wang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Han, Z., Liu, Y., Wang, Y., Men, C., Wang, L., Wang, X., Xie, W., Zhao, L., & Guo, C. (2026). Magnesium‐Enhanced Magnetic Hyperthermia for Triggering Vaccine‐Like Antitumor Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503398
Vancouver
Han Z, Liu Y, Wang Y, Men C, Wang L, Wang X, et al. Magnesium‐Enhanced Magnetic Hyperthermia for Triggering Vaccine‐Like Antitumor Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503398
BibTeX
@article{Han2026,
author = {Han, Zhenyuan and Liu, Yan and Wang, Yifei and Men, Changhe and Wang, Lin and Wang, Xuelin and Xie, Wensheng and Zhao, Lingyun and Guo, Chuanbin},
title = {Magnesium‐Enhanced Magnetic Hyperthermia for Triggering Vaccine‐Like Antitumor Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503398}
}
EUVIMED